This page lists the SEC filings reported by New Leaf Biopharma Opportunities II, L.P..
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2022-02-11 | New Leaf Biopharma Opportunities II, L.P. | Aravive, Inc. | 946,423 | 4.5% | EDGAR |
| SC 13G/A | 2020-02-13 | New Leaf Biopharma Opportunities II, L.P. | Aravive, Inc. | 946,423 | 6.3% | EDGAR |
| SC 13G/A | 2019-02-13 | New Leaf Biopharma Opportunities II, L.P. | Aravive, Inc. | 970,659 | 8.7% | EDGAR |
| SC 13G | 2018-11-06 | New Leaf Biopharma Opportunities II, L.P. | PROTEON THERAPEUTICS INC | 1,523,200 | 8.6% | EDGAR |
| SC 13G | 2018-07-24 | New Leaf Biopharma Opportunities II, L.P. | Versartis, Inc. | 2,247,000 | 6.2% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.